{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:38:37Z","timestamp":1787841517298,"version":"build-2784847793"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","award":["Pfizer Inc."],"award-info":[{"award-number":["Pfizer Inc."]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12282-026-01865-0","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:15:33Z","timestamp":1782285333000},"page":"991-1003","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial"],"prefix":"10.1007","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct03423199","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Takashi","family":"Yamanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joohyuk","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohito","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Feng","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Shen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Chin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Hae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Yun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yasojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Aogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hoon","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Sim","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Ming","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Umeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Kuchiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"1865_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1865_CR2","doi-asserted-by":"publisher","first-page":"101541","DOI":"10.1016\/j.esmoop.2023.101541","volume":"8","author":"SA Im","year":"2023","unstructured":"Im SA, Gennari A, Park YH, Kim JH, Jiang ZF, Gupta S, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer. ESMO Open. 2023;8:101541.","journal-title":"ESMO Open"},{"key":"1865_CR3","doi-asserted-by":"publisher","first-page":"689562","DOI":"10.3389\/fonc.2021.689562","volume":"11","author":"S Xu","year":"2021","unstructured":"Xu S, Liu Y, Zhang T, Zheng J, Lin W, Cai J, et al. The global, regional, and national burden and trends of breast cancer from 1990 to 2019: results from the Global Burden of Disease Study 2019. Front Oncol. 2021;11:689562.","journal-title":"Front Oncol"},{"key":"1865_CR4","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/jnci\/djz090","volume":"111","author":"CH Lin","year":"2019","unstructured":"Lin CH, Yap YS, Lee KH, Im SA, Naito Y, Yeo W, et al. Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population. J Natl Cancer Inst. 2019;111:1298\u2013306.","journal-title":"J Natl Cancer Inst"},{"key":"1865_CR5","doi-asserted-by":"publisher","first-page":"16252","DOI":"10.1038\/srep16252","volume":"5","author":"N Bhoo-Pathy","year":"2015","unstructured":"Bhoo-Pathy N, Verkooijen HM, Tan EY, Miao H, Taib NA, Brand JS, et al. Trends in presentation, management and survival of patients with de novo metastatic breast cancer in a Southeast Asian setting. Sci Rep. 2015;5:16252.","journal-title":"Sci Rep"},{"key":"1865_CR6","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andr\u00e9 F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623\u201349.","journal-title":"Ann Oncol"},{"key":"1865_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22:331\u201357.","journal-title":"J Natl Compr Canc Netw"},{"key":"1865_CR8","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925\u201336.","journal-title":"N Engl J Med"},{"key":"1865_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209\u201319.","journal-title":"N Engl J Med"},{"key":"1865_CR10","first-page":"1","volume":"5","author":"SA Im","year":"2019","unstructured":"Im SA, Mukai H, Park IH, Masuda N, Shimizu C, Kim SB, et al. Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: results from the phase III, randomized PALOMA-2 study. J Glob Oncol. 2019;5:1\u201319.","journal-title":"J Glob Oncol"},{"key":"1865_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/JGO.2016.008318","volume":"3","author":"H Iwata","year":"2017","unstructured":"Iwata H, Im SA, Masuda N, Im YH, Inoue K, Rai Y, et al. PALOMA-3: Phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in Asian patients. J Glob Oncol. 2017;3:289\u2013303.","journal-title":"J Glob Oncol"},{"key":"1865_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejca.2022.08.012","volume":"175","author":"B Xu","year":"2022","unstructured":"Xu B, Hu X, Li W, Sun T, Shen K, Wang S, et al. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: primary results from PALOMA-4. Eur J Cancer. 2022;175:236\u201345.","journal-title":"Eur J Cancer"},{"key":"1865_CR13","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S0140-6736(14)62038-9","volume":"385","author":"C Allemani","year":"2015","unstructured":"Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995\u20132009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385:977\u20131010.","journal-title":"Lancet"},{"key":"1865_CR14","doi-asserted-by":"publisher","first-page":"100573","DOI":"10.1016\/j.lanepe.2022.100573","volume":"26","author":"M Meegdes","year":"2023","unstructured":"Meegdes M, Geurts SME, Erdkamp FLG, Dercksen MW, Vriens B, Aaldering KNA, et al. Real-world time trends in overall survival, treatments and patient characteristics in HR+\/HER2- metastatic breast cancer: an observational study of the SONABRE Registry. Lancet Reg Health Eur. 2023;26:100573.","journal-title":"Lancet Reg Health Eur"},{"key":"1865_CR15","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2188\/jea.JE20170103","volume":"28","author":"A Yoshimura","year":"2018","unstructured":"Yoshimura A, Ito H, Nishino Y, Hattori M, Matsuda T, Miyashiro I, et al. Recent improvement in the long-term survival of breast cancer patients by age and stage in Japan. J Epidemiol. 2018;28:420\u20137.","journal-title":"J Epidemiol"},{"key":"1865_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s12282-024-01575-5","volume":"31","author":"T Yoshinami","year":"2024","unstructured":"Yoshinami T, Nagai SE, Hattori M, Okamura T, Watanabe K, Nakayama T, et al. Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study. Breast Cancer. 2024;31:621\u201332.","journal-title":"Breast Cancer"},{"key":"1865_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/ajco.13958","volume":"19","author":"X Tao","year":"2023","unstructured":"Tao X, Li T, Gandomkar Z, Brennan PC, Reed WM. Incidence, mortality, survival, and disease burden of breast cancer in China compared to other developed countries. Asia Pac J Clin Oncol. 2023;19:645\u201354.","journal-title":"Asia Pac J Clin Oncol"},{"key":"1865_CR18","unstructured":"ABC Global Alliance. Advanced breast cancer (ABC) global charter. 2022."},{"key":"1865_CR19","doi-asserted-by":"publisher","unstructured":"Xu B, Hu X, Li W, Sun T, Shen K, Huang C et al. Patient-reported quality of life in Asian patients with ER+\/HER2- advanced breast cancer treated with palbociclib plus letrozole in the PALOMA-4 trial. Chin Med J (Engl). 2024. https:\/\/doi.org\/10.1097\/CM9.0000000000003122","DOI":"10.1097\/CM9.0000000000003122"},{"key":"1865_CR20","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/annonc\/mdy012","volume":"29","author":"HS Rugo","year":"2018","unstructured":"Rugo HS, Di\u00e9ras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, et al. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol. 2018;29:888\u201394.","journal-title":"Ann Oncol"},{"key":"1865_CR21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41523-024-00684-w","volume":"10","author":"E Noguchi","year":"2024","unstructured":"Noguchi E, Yamanaka T, Mukai H, Yamamoto N, Chung CF, Lu YS, et al. A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive\/HER2-negative advanced breast cancer. NPJ Breast Cancer. 2024;10:76.","journal-title":"NPJ Breast Cancer"},{"key":"1865_CR22","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1001\/jamaoncol.2019.0620","volume":"5","author":"YS Yap","year":"2019","unstructured":"Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, et al. Insights into breast cancer in the East vs the West: a review. JAMA Oncol. 2019;5:1489\u201396.","journal-title":"JAMA Oncol"},{"key":"1865_CR23","doi-asserted-by":"publisher","first-page":"113420","DOI":"10.1016\/j.ejca.2023.113420","volume":"196","author":"JA Garc\u00eda-S\u00e1enz","year":"2024","unstructured":"Garc\u00eda-S\u00e1enz JA, Marm\u00e9 F, Untch M, Bonnefoi H, Kim SB, Bear H, et al. Patient-reported outcomes in high-risk HR+\/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPE(B) study. Eur J Cancer. 2024;196:113420.","journal-title":"Eur J Cancer"},{"key":"1865_CR24","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/annonc\/mdw139","volume":"27","author":"N Harbeck","year":"2016","unstructured":"Harbeck N, Iyer S, Turner N, Cristofanilli M, Ro J, Andr\u00e9 F, et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol. 2016;27:1047\u201354.","journal-title":"Ann Oncol"},{"key":"1865_CR25","unstructured":"EORTC Quality of Life Group. EORTC QLQ-C30 (version 3). 1995."},{"key":"1865_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"1865_CR27","unstructured":"Wintner LM, Sztankay M, Aaronson NK, Bottomley A, Velikova G, de Leeuw V et al. EORTC Quality of Life Group Manual for the use of EORTC measures in daily clinical practice. 2016; 31 January 2025."},{"key":"1865_CR28","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1200\/JCO.1996.14.10.2756","volume":"14","author":"MA Sprangers","year":"1996","unstructured":"Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14:2756\u201368.","journal-title":"J Clin Oncol"},{"key":"1865_CR29","volume-title":"Quality of life: the assessment, analysis and reporting of patient-reported outcomes","author":"P Fayers","year":"2016","unstructured":"Fayers P, Machin D. Quality of life: the assessment, analysis and reporting of patient-reported outcomes. 3rd ed. Chichester, UK: Wiley-Blackwell; 2016.","edition":"3"},{"key":"1865_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139\u201344.","journal-title":"J Clin Oncol"},{"key":"1865_CR31","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.breast.2014.08.004","volume":"23","author":"CS Cleeland","year":"2014","unstructured":"Cleeland CS, Mayer M, Dreyer NA, Yim YM, Yu E, Su Z, et al. Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study. Breast. 2014;23:763\u20139.","journal-title":"Breast"},{"key":"1865_CR32","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904\u201315.","journal-title":"Lancet Oncol"},{"key":"1865_CR33","doi-asserted-by":"publisher","first-page":"175883592094306","DOI":"10.1177\/1758835920943065","volume":"12","author":"N Harbeck","year":"2020","unstructured":"Harbeck N, Franke F, Villanueva-Vazquez R, Lu YS, Tripathy D, Chow L, et al. Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7). Ther Adv Med Oncol. 2020;12:1758835920943065.","journal-title":"Ther Adv Med Oncol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01865-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01865-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01865-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:59:05Z","timestamp":1787839145000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01865-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1865"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01865-0","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Takashi Yamanaka has received honoraria from AstraZeneca, Chugai Pharma, Daiichi Sankyo, Eisai, Lilly, Kyowa Kirin, Gilead Sciences, and Pfizer; consultancy\/advisory fees from Daiichi Sankyo, Lilly, and Pfizer. Joohyuk Sohn has received research funding from Seagen, MSD, Roche, Pfizer, Novartis, AstraZeneca, Lilly, GSK, Boehringer Ingelheim, Sanofi, Daiichi Sankyo, Qurient, Dragonfly, Eikon, Gilead, Celcuity, Bristol Myers Squibb, HLB Life Science, Sermonix Pharmaceuticals, Olema, Hanmi Pharm, Ildong Pharmaceutical, and Samyang Holdings. Kazuki Sudo has received honoraria from AstraZeneca, Pfizer, Eisai, and Nihon Medi-Physics Co.; research funding from Nano Carrier, Daiichi Sankyo, AstraZeneca, Pfizer, Amgen, PRAHealth Sciences, Takeda, and Merck. Hirofumi Mukai has received honoraria or lecture fees from Takeda and Taiho Pharmaceutical. Naohito Yamamoto has received research funding from AstraZeneca and Pfizer. Chi-Feng Chung has received advisory role\/speaker honoraria from AstraZeneca, Daiichi Sankyo, Pfizer, Roche, and Novartis. Yen-Shen Lu has received grant support\/research collaborations from Novartis, Pfizer, MSD, Roche, AstraZeneca, Daiichi Sankyo, and ACT Genomics; advisory board\/speaker invitation from Novartis, Pfizer, MSD, Roche, AstraZeneca, Eisai, Eli Lily, Daiichi Sankyo, and EuroPharma; conference support from Novartis, Eisai, Gilead, and MSD. Kyung-Hun Lee has received honoraria or lecture fees from AstraZeneca, Eli Lilly, Novartis, Pfizer, and Everest Medicine. Soo-Chin Lee has received honoraria from Pfizer, Novartis, AstraZeneca, ACT Genomics, Lilly, MSD, Roche, Gilead Sciences, Daiichi Sankyo, and DKSH; consulting\/advisory fees from Pfizer, Novartis, AstraZeneca, MSD, Roche, Gilead Sciences, and Daiichi Sankyo; speakers\u2019 fees from Pfizer, Novartis, AstraZeneca, Roche, and MSD; research funding from Pfizer, Eisai, Taiho Pharmaceutical, ACT Genomics, and Karyopharm Therapeutics; travel\/accommodation expenses from Amgen, Pfizer, and Roche. Tsutomu Iwasa has no competing financial or non-financial interests. Hiroji Iwata has received honoraria and research funding from AstraZeneca K.K., and Pfizer; fees for promotional materials from AstraZeneca. Kenichi Watanabe has received speaker\u2019s honoraria from Chugai, Eli Lilly, Nippon-Kayaku, Kyowa Kirin, Novartis, Taiho, Eisai, Pfizer, Shionogi, Daiichi Sankyo, and AstraZeneca. Kyung Hae Jung has had consulting or advisory roles for AstraZeneca, Bixink, Daewoong Pharmaceuticals, Daiichi Sankyo, Eisai, Everest Medicine, ImmuneOncia, MSD, Novartis, Pfizer, Roche, and Takeda Pharmaceuticals. Yuko Tanabe has received research funding from MSD. Seok Yun Kang, Hiroyuki Yasojima, and Kenjiro Aogi have no competing financial or non-financial interests. Eriko Tokunaga has received personal fees for lectures from Eli Lilly, AstraZeneca, and Daiichi Sankyo. Sung Hoon Sim has no competing financial or non-financial interests. Yoon Sim Yap has received honoraria from Novartis, Pfizer, Lilly\/DKSH, AstraZeneca, MSD, Olema, Roche, and Daiichi Sankyo; research funding from Merck Sharp & Dohme; travel, accommodations, expenses from DKSH, AstraZeneca, Pfizer, MSD, Daiichi Sankyo, and Novartis. Koji Matsumoto has received research funding from MSD, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, and Gilead Sciences; honoraria from MSD, Kyowa Kirin, and Chugai. Ling-Ming Tseng has no competing financial or non-financial interests. Yoshiko Umeyama is an employee of Pfizer R&D Japan and owns stock in Pfizer. Emi Noguchi and Tomomi Hata have no competing financial or non-financial interests. Aya Kuchiba has received hono\u00adraria from Chugai Pharma. Taro Shibata has no competing financial or non-financial interests. Kenichi Nakamura has received honoraria from Chugai Pharma, Taiho Pharmaceutical, Takeda, IQVIA, As\u00adtraZeneca, and Lilly; research funding from Astellas Pharma, Eisai, Otsuka, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Takeda, Chugai\/Roche, Novartis, Pfizer, Bristol Myer Squibb Japan, Boehringer Ingelheim Seiyaku, SymBio Pharmaceuticals, Merck, and Servier. Yasuhiro Fujiwara is currently Chief Executive of Pharmaceu\u00adticals and Medical Devices Agency, regulatory agency of Japan, and contributed to this trial until March 2019. Kenji Tamura has no com\u00adpeting financial or non-financial interests. Kan Yonemori has received consulting\/advisory fees from Chugai Pharma, Ono Pharmaceutical, Novartis, Eisai, and OncXerna Therapeutics; honoraria from Eisai, Pfizer, AstraZeneca, Novartis, Taiho Pharmaceutical, Lilly Japan, and Daiichi Sankyo\/AstraZeneca.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The protocol was approved by the institutional review board at each trial site.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declaration"}}]}}